众生药业(002317.SZ)子公司获得一类创新药昂拉地韦颗粒III期临床试验伦理批件

Core Viewpoint - The announcement from Zhongsheng Pharmaceutical (002317.SZ) indicates that its subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., has received approval for a Phase III clinical trial of the innovative drug Anladiwei granules for treating uncomplicated influenza A in children aged 2 to 11 years [1] Group 1 - The clinical trial is a multicenter, randomized, double-blind, positive-controlled study focusing on the safety and efficacy of Anladiwei granules [1] - Anladiwei tablets (brand name: Anruiwei®) are the world's first innovative drug targeting the PB2 subunit of the RNA polymerase of the influenza A virus, designed for the treatment of uncomplicated influenza A in adults [1] - The drug is characterized by rapid action, strong efficacy, and low resistance, and it was approved for market launch by the National Medical Products Administration in May 2025 [1]